...hemagglutinin antigens purified from cultured insect cells. Under an amended 2006 deal, Protein Sciences granted UMN Pharma...
...Hong Kong and Singapore (see BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights from UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...MHLW) for ASP7374 to prevent influenza infection. The submission triggered an undisclosed milestone payment to UMN Pharma...
...Protein Sciences will receive a portion of the milestone under an amended 2006 deal granting UMN Pharma...
...BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights in Japan under its deal with UMN Pharma...

...and royalties, but declined to disclose financial terms. UMN could not be reached for details. UMN Pharma Inc....

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...seasonal influenza infection in adults ages 18-49 years (see BioCentury, Jan. 21, 2013). Astellas and UMN Pharma...
...commercialization rights to the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...Astellas and UMN Pharma said all subjects were vaccinated in an open-label, Japanese Phase III trial evaluating...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...Astellas and UMN Pharma said all subjects were vaccinated in a double-blind, Japanese Phase III trial comparing...
...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...and exclusive commercialization rights for the product in Korea. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...seasonal influenza vaccine made with recombinant hemagglutinin antigens purified from cultured insect cells. Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...to prevent seasonal influenza in adults ages 18-49 years (see BioCentury, Jan. 21). Astellas and UMN Pharma...
...commercialization rights for the product in Korea from UMN. Protein Sciences Corp. , Meriden, Conn. UMN Pharma Inc....

...Yakult will be responsible for development and commercialization. API Co. Ltd. , Gifu City, Japan UMN Pharma Inc....